Dr. Nagourney's Blog


Informative articles sent right to your inbox. Subscribe to Dr. Nagourney's blog today.

Is There a Role for PI3k Inhibitors in Breast Cancer? Maybe.
By Robert A. Nagourney, MD
Over the past decades oncologists have learned that cancer is driven by circuits known as signal transduction pathways. The first breakthroughs were in chronic myelogenous leukemia treatment (CML) where a short circuit in the gene as c-Abl...
Toward A 100% Response Rate in Human Cancer
By Robert A. Nagourney, MD
Oncologists confront numerous hurdles as they attempt to apply the new cancer prognostic and predictive tests. Among them are...
Breast Cancer-Same Age, Same Diagnosis, Different Functional Profiles
By Robert A. Nagourney, MD
A day in the life of advanced breast cancer. Two different 37-year-old breast cancer patients, both mothers of young children,...
Triple Negative Breast Cancer - Worse or Just Different?
By Robert A. Nagourney, MD
The term “triple negative breast cancer” (TNBC) is applied to a subtype of breast cancers that do not express the estrogen or...
What Exactly are the Targets of Targeted Therapy?
By Robert A. Nagourney, MD
The term “targeted therapy” has entered common parlance. Like personalized medicine, targeted therapy is a generic description...
Using Functional Profiles to Inform Genomics - Gynecologic Cancer Case
By Robert A. Nagourney, MD
Recently, I was asked to evaluate a charming young woman with an unusual gynecologic primary. She had received numerous forms...
Activity of MEK/ERK and PI3K/mTOR Inhibitors Explored
By Robert A. Nagourney, MD
The Sunday, April 3, 2011, experimental and molecular therapeutics session at the AACR 102nd annual meeting included our...

browse by topic

Select A topic

View All Topics

most popular articles

patient story

How We Helped David Hanbidge

"I'll never forget the day when the doctor took my wife and me to a small back office and told us the horrible news…I had the very worst kind of lung cancer..."   Read about how we helped David.